scholarly article | Q13442814 |
P2093 | author name string | Liyue Tong | |
Robert Timmerman | |||
Jeffrey Meyer | |||
Ramzi Abdulrahman | |||
Paul Weatherall | |||
Thomas Boike | |||
William Rule | |||
L. Chinsoo Cho | |||
Roderich E. Schwarz | |||
P2860 | cites work | Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy | Q40014973 |
Surgical treatment of colorectal metastases to the liver | Q40559150 | ||
Analysis of radiation-induced liver disease using the Lyman NTCP model. | Q44048914 | ||
Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial | Q44306113 | ||
Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trial | Q44586518 | ||
Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer | Q48151239 | ||
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases | Q49186620 | ||
Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. | Q52142739 | ||
Optimization of radiation therapy II: the critical-voxel model. | Q52693730 | ||
An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. | Q53133028 | ||
Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. | Q53519999 | ||
Radiofrequency Ablation of 100 Hepatic Metastases with a Mean Follow-Up of More Than 1 Year | Q60629797 | ||
Stereotactic High Dose Fraction Radiation Therapy of Extracranial Tumors Using An Accelerator: Clinical experience of the first thirty-one patients | Q71783537 | ||
Resection of colorectal liver metastases | Q72216092 | ||
Ultrasound-guided percutaneous alcohol injection of small liver metastases. Results in 40 patients | Q72736695 | ||
Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma | Q74081538 | ||
Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients | Q74543135 | ||
Stereotactic radiotherapy of targets in the lung and liver | Q77483854 | ||
Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases | Q79465276 | ||
Stereotactic radiotherapy of primary liver cancer and hepatic metastases | Q80282837 | ||
A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases | Q80394070 | ||
[Stereotactic radiation therapy for liver metastases] | Q81721571 | ||
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases | Q83412928 | ||
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions). | Q31117028 | ||
Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies | Q33382057 | ||
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases | Q33874670 | ||
Stereotactic body radiation therapy for inoperable early stage lung cancer | Q34010065 | ||
Trends in long-term survival following liver resection for hepatic colorectal metastases | Q34523502 | ||
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases | Q34557044 | ||
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer | Q34575077 | ||
Cryotherapy in the treatment of liver metastases from colorectal cancer | Q34598668 | ||
A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions | Q34723820 | ||
Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: technique and prospective results | Q36678756 | ||
Stereotactic body radiation therapy in multiple organ sites | Q36756959 | ||
Surgical therapy for colorectal metastases to the liver | Q36832322 | ||
Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? | Q36956302 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | dose fractionation | Q5299253 |
P304 | page(s) | 1081-1087 | |
P577 | publication date | 2010-11-03 | |
P1433 | published in | Annals of Surgical Oncology | Q2853069 |
P1476 | title | Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases | |
Phase I Dose-Escalation Study of Stereotactic Body Radiotherapy in Patients With Hepatic Metastases | |||
P478 | volume | 18 |
Q36415438 | A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases |
Q39415601 | A single reference measurement can predict liver tumor motion during respiration |
Q48492687 | Clinical experience with planning, quality assurance, and delivery of burst-mode modulated arc therapy |
Q37308725 | Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). |
Q36945323 | Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases |
Q87893313 | Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases |
Q34655878 | Current and emerging treatment options for uveal melanoma |
Q35782954 | Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection |
Q27015651 | Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice |
Q61054503 | Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer |
Q92315128 | High versus low dose Stereotactic Body Radiation Therapy for hepatic metastases |
Q50324017 | Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy |
Q40395624 | Local ablative radiotherapy of oligometastatic colorectal cancer |
Q33645887 | Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients |
Q30415022 | Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements |
Q35905087 | Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions |
Q89481572 | MRI-guided adaptive radiotherapy for liver tumours: visualising the future |
Q91675162 | Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions |
Q34974386 | Minimally invasive local therapies for liver cancer |
Q26744490 | Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation |
Q33779859 | Multidisciplinary approach of colorectal cancer liver metastases |
Q38091331 | Oligometastases: the new paradigm and options for radiotherapy. A critical review |
Q26828767 | Oligometastasis and oligo-recurrence: more than a mirage |
Q50650651 | Optimization of stereotactic body radiotherapy treatment planning using a multicriteria optimization algorithm. |
Q37458034 | Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma |
Q38685466 | Radiobiology of stereotactic body radiation therapy (SBRT). |
Q26864247 | Review and uses of stereotactic body radiation therapy for oligometastases |
Q37708013 | Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer |
Q36383996 | Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors |
Q64094411 | Single community-based institutional series of stereotactic body radiation therapy (SBRT) for treatment of liver metastases |
Q60957976 | Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis: A dose escalation study |
Q37048588 | Single-dose radiosurgical treatment for hepatic metastases--therapeutic outcome of 138 treated lesions from a single institution |
Q49787609 | Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry |
Q39598540 | Stereotactic ablative radiotherapy for oligometastatic disease in liver |
Q90478112 | Stereotactic body radiation therapy and radiofrequency ablation for the treatment of liver metastases: How and when? |
Q36360066 | Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review. |
Q35971469 | Stereotactic body radiation therapy for liver metastases from colorectal cancer: analysis of safety, feasibility, and early outcomes |
Q50355067 | Stereotactic body radiation therapy for liver metastasis - The linac-based Greater Poland Cancer Centre practice |
Q33919725 | Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors |
Q21129307 | Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors |
Q33769424 | Stereotactic body radiation therapy using the CyberKnife(®) system for patients with liver metastases |
Q87499954 | Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy |
Q37152196 | Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83-100 Gy in five fractions. |
Q58790310 | Stereotactic body radiotherapy using the CyberKnife system in the treatment of patients with liver metastases: state of the art |
Q38175120 | Stereotactic body radiotherapy: a critical review for nonradiation oncologists |
Q35731820 | Stereotactic radiation therapy for liver metastases: factors affecting local control and survival |
Q50061872 | Strategies for prediction and mitigation of radiation-induced liver toxicity. |
Q33706721 | Strategies to tackle the challenges of external beam radiotherapy for liver tumors |
Q92372917 | Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality? |
Q32173610 | Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer. |
Q92725532 | Technical Assessment of an Automated Treatment Planning on Dose Escalation of Pancreas Stereotactic Body Radiotherapy |
Q37878852 | The role of local therapy in the management of lung and liver oligometastases. |
Q39371182 | Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer |
Q38191920 | Treatment of metastatic liver tumors using stereotactic ablative radiotherapy |